journal article·2024-11Open access

Design Principles and Applications of Ionic Liquids for Transdermal Drug Delivery

Sai Gao, Xueqing Cheng, Ming Zhang, Qiong Dai, Chaoyong Liu, Yunfeng Lu

Advanced Science· Volume 11· Issue 43

Abstract

Abstract Ionic liquids (ILs) are salts with melting points typically <100 °C, composed of specific anions and cations. Recently, IL application has expanded into material engineering and biomedicine. Due to their unique properties, ILs have garnered significant interest in pharmacological research as solubilizers, transdermal absorption enhancers, antibacterial agents, and stabilizers of insoluble pharmaceutical active ingredients. The improvement of skin permeability by ILs is closely associated with their specific physicochemical characteristics, which are identified by their ionic composition. However, the existing literature on transdermal medication administration is insufficient in terms of a comprehensive knowledge base. This review provides a comprehensive assessment of the design principles involved in IL synthesis. Additionally, it discusses the methods utilized to assess skin permeability and provides a focused outline of IL application in transdermal drug administration.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Ionic liquids properties and applications · Advancements in Transdermal Drug Delivery · Surfactants and Colloidal Systems

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Beijing Advanced Innovation Center for Soft Matter Science and Engineering Beijing University of Chemical Technology Beijing 100029 P. R. China

College of Life Science and Technology Beijing University of Chemical Technology Beijing 100029 P. R. China

Department of Pathology Peking University International Hospital Beijing 102206 P. R. China

Funding

National Key Research and Development Program of China

References (100+)

Show source-provided references
1. 10.1016/j.ejps.2021.10591510.1016/j.ejps.2021.105915 ↗
2. 10.3390/ijms22211199110.3390/ijms222111991 ↗
3. 10.1016/j.molliq.2021.11531010.1016/j.molliq.2021.115310 ↗
4. 10.1016/j.addr.2021.11399710.1016/j.addr.2021.113997 ↗
5. 10.3390/ijms2209433810.3390/ijms22094338 ↗
6. 10.1002/EXP.2021017010.1002/EXP.20210170 ↗
7. 10.1358/mf.2000.22.5.79664910.1358/mf.2000.22.5.796649 ↗
8. 10.1177/10499091960130060810.1177/104990919601300608 ↗
9. 10.1016/0002-9149(88)90090-210.1016/0002-9149(88)90090-2 ↗
10. 10.4103/aer.AER_68_1710.4103/aer.AER_68_17 ↗
11. Wong W. F. · Med. · 2023 · 59 · 778
12. 10.1016/j.addr.2014.01.00710.1016/j.addr.2014.01.007 ↗
13. 10.1166/jbn.2017.247410.1166/jbn.2017.2474 ↗
14. 10.1016/j.biopha.2018.10.07810.1016/j.biopha.2018.10.078 ↗
15. 10.1002/marc.20220003710.1002/marc.202200037 ↗
16. 10.1007/s13346-021-00898-610.1007/s13346-021-00898-6 ↗
17. 10.3389/fphar.2015.0021910.3389/fphar.2015.00219 ↗
18. 10.1186/s41702-020-0058-710.1186/s41702-020-0058-7 ↗
19. 10.1016/j.ijpharm.2013.02.04010.1016/j.ijpharm.2013.02.040 ↗
20. 10.1039/c2an35220f10.1039/c2an35220f ↗
21. 10.1016/S1461-5347(00)00295-910.1016/S1461-5347(00)00295-9 ↗
22. 10.1002/ejic.20170055310.1002/ejic.201700553 ↗
23. 10.1021/acs.chemrev.6b0059410.1021/acs.chemrev.6b00594 ↗
24. 10.1021/acs.chemrev.7b0024610.1021/acs.chemrev.7b00246 ↗
25. 10.1016/j.fluid.2004.02.00310.1016/j.fluid.2004.02.003 ↗
26. 10.1002/cmdc.20110008210.1002/cmdc.201100082 ↗
27. 10.1002/9781119640240.ch610.1002/9781119640240.ch6 ↗
28. 10.1007/s11356-015-4794-y10.1007/s11356-015-4794-y ↗
29. 10.1039/b706677p10.1039/b706677p ↗
30. 10.1016/j.molliq.2019.11216610.1016/j.molliq.2019.112166 ↗
31. 10.1002/tcr.20110003610.1002/tcr.201100036 ↗
32. 10.1002/advs.20200481910.1002/advs.202004819 ↗
33. 10.1039/D3CS00510K10.1039/D3CS00510K ↗
34. Zandu S. K. · Curr. Drug Metab. · 2020 · 12 · 26
35. 10.1007/s11581-021-04201-y10.1007/s11581-021-04201-y ↗
36. 10.1002/tcr.20230002610.1002/tcr.202300026 ↗
37. 10.1016/j.addr.2023.11515710.1016/j.addr.2023.115157 ↗
38. 10.1039/C9CS00016J10.1039/C9CS00016J ↗
39. 10.1016/j.scitotenv.2021.14730910.1016/j.scitotenv.2021.147309 ↗
40. 10.1016/j.ejpb.2015.04.03410.1016/j.ejpb.2015.04.034 ↗
41. 10.1021/mp500790t10.1021/mp500790t ↗
42. 10.1016/j.cocis.2007.10.00510.1016/j.cocis.2007.10.005 ↗
43. 10.1016/j.cocis.2016.05.01110.1016/j.cocis.2016.05.011 ↗
44. 10.3183/npprj-2015-30-01-p105-11110.3183/npprj-2015-30-01-p105-111 ↗
45. 10.1016/j.ijpharm.2020.11933510.1016/j.ijpharm.2020.119335 ↗
46. 10.1016/j.jconrel.2018.07.02910.1016/j.jconrel.2018.07.029 ↗
47. 10.1002/adfm.20200425710.1002/adfm.202004257 ↗
48. 10.1002/adma.20190110310.1002/adma.201901103 ↗
49. 10.1016/j.ijpharm.2016.11.02010.1016/j.ijpharm.2016.11.020 ↗
50. 10.3390/pharmaceutics1102009610.3390/pharmaceutics11020096 ↗
51. 10.3109/10837450.2015.113171810.3109/10837450.2015.1131718 ↗
52. 10.1016/S0169-409X(02)00113-810.1016/S0169-409X(02)00113-8 ↗
53. 10.1016/j.jconrel.2022.09.02510.1016/j.jconrel.2022.09.025 ↗
54. Qi Q. M. · J. Controlled Release · 2019 · 162 · 311
55. 10.1016/j.ijpharm.2021.12056010.1016/j.ijpharm.2021.120560 ↗
56. 10.1039/C6RA16926K10.1039/C6RA16926K ↗
57. 10.1021/acs.molpharmaceut.0c0059810.1021/acs.molpharmaceut.0c00598 ↗
58. 10.1080/03639045.2017.134978810.1080/03639045.2017.1349788 ↗
59. 10.1016/j.ijpharm.2022.12172410.1016/j.ijpharm.2022.121724 ↗
60. 10.1016/j.jconrel.2022.07.03510.1016/j.jconrel.2022.07.035 ↗
61. 10.1007/s11095-022-03238-610.1007/s11095-022-03238-6 ↗
62. 10.1016/j.ijpharm.2017.10.02410.1016/j.ijpharm.2017.10.024 ↗
63. 10.1248/cpb.41.143410.1248/cpb.41.1434 ↗
64. 10.1002/cmdc.20160048010.1002/cmdc.201600480 ↗
65. 10.1021/acs.chemrev.6b0056210.1021/acs.chemrev.6b00562 ↗
66. 10.1016/j.jconrel.2016.09.00310.1016/j.jconrel.2016.09.003 ↗
67. 10.1016/j.colcom.2019.10020410.1016/j.colcom.2019.100204 ↗
68. 10.1039/c2cs15362a10.1039/c2cs15362a ↗
69. 10.1016/j.ijpharm.2019.01.02110.1016/j.ijpharm.2019.01.021 ↗
70. 10.1021/acssuschemeng.0c0341910.1021/acssuschemeng.0c03419 ↗
71. 10.1021/acs.jpcb.9b0179910.1021/acs.jpcb.9b01799 ↗
72. 10.1002/adma.20190110310.1002/adma.201901103 ↗
73. 10.1021/acs.molpharmaceut.0c0059810.1021/acs.molpharmaceut.0c00598 ↗
74. 10.3390/pharmaceutics1406115210.3390/pharmaceutics14061152 ↗
75. 10.1080/1071754080200689810.1080/10717540802006898 ↗
76. 10.3390/pharmaceutics1412281810.3390/pharmaceutics14122818 ↗
77. 10.1038/s41598-019-56731-110.1038/s41598-019-56731-1 ↗
78. 10.1007/s13346-021-00951-410.1007/s13346-021-00951-4 ↗
79. 10.3390/pharmaceutics1606081710.3390/pharmaceutics16060817 ↗
80. 10.1016/j.ejpb.2007.12.00510.1016/j.ejpb.2007.12.005 ↗
81. 10.1021/acsbiomaterials.9b0024310.1021/acsbiomaterials.9b00243 ↗
82. 10.1007/s11095-022-03394-910.1007/s11095-022-03394-9 ↗
83. 10.1007/978-981-16-7152-4_1710.1007/978-981-16-7152-4_17 ↗
84. 10.1016/j.ijpharm.2011.10.03110.1016/j.ijpharm.2011.10.031 ↗
85. 10.1007/s11095-022-03322-x10.1007/s11095-022-03322-x ↗
86. 10.1080/17460441.2017.134421010.1080/17460441.2017.1344210 ↗
87. 10.1016/j.ijpharm.2013.08.01010.1016/j.ijpharm.2013.08.010 ↗
88. 10.1039/c2cp40122c10.1039/c2cp40122c ↗
89. 10.3390/pharmaceutics1604048010.3390/pharmaceutics16040480 ↗
90. 10.1016/j.ijpharm.2015.09.06610.1016/j.ijpharm.2015.09.066 ↗
91. 10.1021/acsami.2c1563610.1021/acsami.2c15636 ↗
92. Berton P. · 2021
93. 10.1002/adfm.20200425710.1002/adfm.202004257 ↗
94. 10.1007/s10924-020-01813-910.1007/s10924-020-01813-9 ↗
95. 10.1016/j.ijbiomac.2015.10.03110.1016/j.ijbiomac.2015.10.031 ↗
96. 10.1021/acsami.1c0311110.1021/acsami.1c03111 ↗
97. 10.2217/fmb-2019-029010.2217/fmb-2019-0290 ↗
98. 10.1016/j.ejps.2019.10504210.1016/j.ejps.2019.105042 ↗
99. 10.1208/s12249-021-01956-510.1208/s12249-021-01956-5 ↗
100. 10.1016/j.actbio.2020.08.02310.1016/j.actbio.2020.08.023 ↗